The News Review:
- Indian arms of Pfizer GSK may benefit from global job cuts
- Research Indicates Synthetic Compound NV-52 May Be Useful in Treatment…
- New UVa School of Medicine and EVMS Partnership
Indian arms of Pfizer GSK may benefit from global job cuts
Livemint – Nov 13, 2007
The plan includes the closure of five R&D sites and the relocation of some projects. ?Since the intellectual property issues are a concern in India there is still no clarity about new investments by the parent company here. However there could be more works coming to India in the clinical research services? said Kewal Handa managing director Pfizer India on the sidelines of a pharma event in Mumbai last week. Pfizer was one of the first pharmaceutical companies to establish a dedicated clinical research division in India. About two-thirds of this division?s clinical research portfolio relates to human studies executed on behalf of Pfizer Global Research & Development teams.
Research Indicates Synthetic Compound NV-52 May Be Useful in Treatment…
marketwire.com – Nov 13, 2007
“Improved maintenance therapy remains the greatest unmetmedical need in treating IBD with the challenge in drug development beinga non-toxic agent that will maintain disease remission. NV-52 is part of an emerging class of synthetic isoflavonoid compounds. Isoflavones have been reported to have a wide range of pharmaceuticaleffects in animal studies and in clinical research. Novogen Limited researchers hope the compound could one day become aleading therapy for the treatment and maintenance of remission in IBD. About Novogen Limited:Novogen Limited (ASX:.
New UVa School of Medicine and EVMS Partnership
WCAV – Nov 13, 2007
The schools will hire a clinical research manager to be based on the EVMS campus in Norfolk and jointly pay the salary which will be less than $100000 officials said. “This is a nice opportunity for both institutions to take advantages of the strengths at the two places” Dr. Ron Turner senior associate dean for clinical research at U. School of Medicine said during a teleconference call with reporters.
